Valuation check: PLSE's profit margin is -23672.06%, below the Healthcare sector average of 15.29%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
The latest profit margin for PLSE is -23672.06% as of March 2026. That compares with -7240.75% in the prior-year period — down 226.9% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Pulse Biosciences's historical trend and sector peers before judging valuation or financial health.
Over the past year, PLSE's profit margin moved from -7240.75% to -23672.06% — a 226.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pulse Biosciences's valuation or profitability profile.
Against Healthcare companies, PLSE currently prints -23672.06% for profit margin, while the sector average sits near 15.29%. That is roughly 154891.3% below the sector mean. Large gaps often invite a closer look at Pulse Biosciences's growth, margins, and balance sheet.
Profit Margin shows how effectively Pulse Biosciences converts resources into returns. At -23672.06%, PLSE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -7240.75% in the prior-year period — down 226.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting PLSE's profit margin (-23672.06%), review year-over-year change from -7240.75%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.